Peter Cicala
Directeur/Bestuurslid bij ETERNA THERAPEUTICS INC.
Profiel
Peter Cicala is the founder of Boundless Bio, Inc. (founded in 2019).
He is currently working as an Independent Director at Eterna Therapeutics, Inc. since 2024.
Previously, he held the position of Chief Intellectual Property Counsel at Intercept Pharmaceuticals, Inc. from 2020 to 2021 and Chief Patent Counsel at Celgene Corp.
from 2014 to 2019.
Mr. Cicala completed his undergraduate degree at Fairleigh Dickinson University and his graduate degree at Seton Hall University School of Law.
Actieve functies van Peter Cicala
| Bedrijven | Functie | Begin |
|---|---|---|
| ETERNA THERAPEUTICS INC. | Directeur/Bestuurslid | 12-02-2024 |
Eerdere bekende functies van Peter Cicala
| Bedrijven | Functie | Einde |
|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-03-2021 |
| CELGENE | Corporate Officer/Principal | 01-11-2019 |
| BOUNDLESS BIO, INC. | Oprichter | - |
Opleiding van Peter Cicala
| Seton Hall University School of Law | Graduate Degree |
| Fairleigh Dickinson University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| ETERNA THERAPEUTICS INC. | Health Technology |
| BOUNDLESS BIO, INC. | Health Technology |
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
